175 related articles for article (PubMed ID: 30771861)
1. Relationship Between Optimism and Outcomes in Patients With Chronic Angina Pectoris.
Fanaroff AC; Prather K; Brucker A; Wojdyla D; Davidson-Ray L; Mark DB; Williams RB; Barefoot J; Weisz G; Ben-Yehuda O; Stone GW; Ohman EM; Alexander KP
Am J Cardiol; 2019 May; 123(9):1399-1405. PubMed ID: 30771861
[TBL] [Abstract][Full Text] [Related]
2. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.
Alexander KP; Weisz G; Prather K; James S; Mark DB; Anstrom KJ; Davidson-Ray L; Witkowski A; Mulkay AJ; Osmukhina A; Farzaneh-Far R; Ben-Yehuda O; Stone GW; Ohman EM
Circulation; 2016 Jan; 133(1):39-47. PubMed ID: 26555329
[TBL] [Abstract][Full Text] [Related]
3. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.
Weisz G; Généreux P; Iñiguez A; Zurakowski A; Shechter M; Alexander KP; Dressler O; Osmukhina A; James S; Ohman EM; Ben-Yehuda O; Farzaneh-Far R; Stone GW;
Lancet; 2016 Jan; 387(10014):136-45. PubMed ID: 26474810
[TBL] [Abstract][Full Text] [Related]
4. Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 Trial.
Gutierrez JA; Karwatowska-Prokopczuk E; Murphy SA; Belardinelli L; Farzaneh-Far R; Walker G; Morrow DA; Scirica BM
Clin Cardiol; 2015 Aug; 38(8):469-75. PubMed ID: 26059896
[TBL] [Abstract][Full Text] [Related]
5. Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial.
Weisz G; Farzaneh-Far R; Ben-Yehuda O; Debruyne B; Montalescot G; Lerman A; Mahmud E; Alexander KP; Ohman EM; White HD; Olmsted A; Walker GA; Stone GW
Am Heart J; 2013 Dec; 166(6):953-959.e3. PubMed ID: 24268208
[TBL] [Abstract][Full Text] [Related]
6. Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial.
Fanaroff AC; James SK; Weisz G; Prather K; Anstrom KJ; Mark DB; Ben-Yehuda O; Alexander KP; Stone GW; Ohman EM
J Am Coll Cardiol; 2017 May; 69(18):2304-2313. PubMed ID: 28473136
[TBL] [Abstract][Full Text] [Related]
7. Role of Ranolazine in Reducing Angina, Subsequent Revascularization, and Healthcare Expenditures in Stable Ischemic Heart Disease.
Rasalingam R; Boden WE
Am J Cardiol; 2019 May; 123(10):1729-1731. PubMed ID: 30922541
[No Abstract] [Full Text] [Related]
8. Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial.
Maron DJ; Spertus JA; Mancini GB; Hartigan PM; Sedlis SP; Bates ER; Kostuk WJ; Dada M; Berman DS; Shaw LJ; Chaitman BR; Teo KK; O'Rourke RA; Weintraub WS; Boden WE;
Am J Cardiol; 2009 Oct; 104(8):1055-62. PubMed ID: 19801024
[TBL] [Abstract][Full Text] [Related]
9. Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris.
Ling H; Packard KA; Burns TL; Hilleman DE
Am J Cardiovasc Drugs; 2013 Dec; 13(6):407-12. PubMed ID: 23873327
[TBL] [Abstract][Full Text] [Related]
10. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
[TBL] [Abstract][Full Text] [Related]
11. Coronary artery disease: a dam in the river for ranolazine.
Head SJ; Kappetein AP
Lancet; 2016 Jan; 387(10014):100-2. PubMed ID: 26474812
[No Abstract] [Full Text] [Related]
12. Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease.
Spertus JA; Jones PG; Maron DJ; O'Brien SM; Reynolds HR; Rosenberg Y; Stone GW; Harrell FE; Boden WE; Weintraub WS; Baloch K; Mavromatis K; Diaz A; Gosselin G; Newman JD; Mavromichalis S; Alexander KP; Cohen DJ; Bangalore S; Hochman JS; Mark DB;
N Engl J Med; 2020 Apr; 382(15):1408-1419. PubMed ID: 32227753
[TBL] [Abstract][Full Text] [Related]
13. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial.
Pfisterer M; Buser P; Osswald S; Allemann U; Amann W; Angehrn W; Eeckhout E; Erne P; Estlinbaum W; Kuster G; Moccetti T; Naegeli B; Rickenbacher P;
JAMA; 2003 Mar; 289(9):1117-23. PubMed ID: 12622581
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
Wilson SR; Scirica BM; Braunwald E; Murphy SA; Karwatowska-Prokopczuk E; Buros JL; Chaitman BR; Morrow DA
J Am Coll Cardiol; 2009 Apr; 53(17):1510-6. PubMed ID: 19389561
[TBL] [Abstract][Full Text] [Related]
15. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs Cooperative randomized trial. Veterans Affairs ACME InvestigatorS.
Folland ED; Hartigan PM; Parisi AF
J Am Coll Cardiol; 1997 Jun; 29(7):1505-11. PubMed ID: 9180111
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Economic Outcomes of Ranolazine Versus Conventional Antianginals Users Among Veterans With Chronic Stable Angina Pectoris.
Bress AP; Dodson JA; King JB; Sauer BC; Reese T; Crook J; Radwanski P; Knippenberg K; Greene T; Nelson RE; Munger MA; Weintraub WS; LaFleur J
Am J Cardiol; 2018 Dec; 122(11):1809-1816. PubMed ID: 30292334
[TBL] [Abstract][Full Text] [Related]
17. Do differences in repeat revascularization explain the antianginal benefits of bypass surgery versus percutaneous coronary intervention?: implications for future treatment comparisons.
Arnold SV; Magnuson EA; Wang K; Serruys PW; Kappetein AP; Mohr FW; Cohen DJ;
Circ Cardiovasc Qual Outcomes; 2012 May; 5(3):267-75. PubMed ID: 22496114
[TBL] [Abstract][Full Text] [Related]
18. Complete Revascularization and Angina-Related Health Status in the ISCHEMIA Trial.
Mavromatis K; Jones PG; Ali ZA; Stone GW; Rhodes GM; Bangalore S; O'Brien S; Genereux P; Horst J; Dressler O; Goodman S; Alexander K; Mathew A; Chen J; Bhargava B; Uxa A; Boden WE; Mark DB; Reynolds HR; Maron DJ; Hochman JS; Spertus JA;
J Am Coll Cardiol; 2023 Jul; 82(4):295-313. PubMed ID: 37468185
[TBL] [Abstract][Full Text] [Related]
19. Usefulness and safety of percutaneous myocardial laser revascularization for refractory angina pectoris.
Salem M; Rotevatn S; Stavnes S; Brekke M; Vollset SE; Nordrehaug JE
Am J Cardiol; 2004 May; 93(9):1086-91. PubMed ID: 15110197
[TBL] [Abstract][Full Text] [Related]
20. Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry).
Storey KM; Wang J; Garberich RF; Bennett NM; Traverse JH; Arndt TL; Schmidt CW; Henry TD
Am J Cardiol; 2020 Aug; 129():1-4. PubMed ID: 32540170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
